Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 2/20 | 0.44 |
| ▸ | PPARA | Q07869 | 2/20 | 0.44 |
| ▸ | CACNA2D1 | P54289 | 10/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6274946 | 1.00 | KMT2A (0.50) | KMT2AFABP5MEN1PPARGPPARA | |
| SCHEMBL5756023 | 0.99 | KMT2A (0.49) | KMT2AFABP5MEN1PPARGPPARA | |
| SCHEMBL5756012 | 0.99 | KMT2A (0.49) | KMT2AFABP5MEN1PPARGPPARA | |
| SCHEMBL20045399 | 0.90 | KMT2A (0.51) | KMT2APPARGPPARA | |
| SCHEMBL5756016 | 0.86 | MEN1 (0.43) | KMT2AFABP5MEN1CACNA2D1 | |
| SCHEMBL6313497 | 0.86 | F9 (0.50) | KMT2AFABP5MEN1CACNA2D1SMN1; SMN2 | |
| SCHEMBL5757213 | 0.86 | F9 (0.50) | KMT2AFABP5MEN1CACNA2D1SMN1; SMN2 | |
| SCHEMBL13318742 | 0.82 | CACNA2D1 (0.42) | KMT2AFABP5MEN1CACNA2D1 | |
| SCHEMBL2586363 | 0.81 | CACNA2D1 (0.49) | KMT2AMEN1CACNA2D1KDM4E | |
| SCHEMBL6270120 | 0.78 | KMT2A (0.49) | KMT2AMEN1PPARGPPARAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2024355-B1 | ALKENE PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2010-07-14 | — | — | EP | disclosed |
| EP-2024355-B1 | ALKENE PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2010-07-14 | — | — | EP | disclosed |
| US-7745463-B2 | Alkene piperidine derivatives as antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-29 | — | — | US | disclosed |
| US-7745463-B2 | Alkene piperidine derivatives as antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-29 | — | — | US | disclosed |
| US-7745463-B2 | Alkene piperidine derivatives as antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-29 | — | — | US | disclosed |
| US-20090253741-A1 | ALKENE PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
| US-20090253741-A1 | ALKENE PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
| US-20090253741-A1 | ALKENE PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
| US-7572810-B2 | Alkene piperidine derivatives as antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572810-B2 | Alkene piperidine derivatives as antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572810-B2 | Alkene piperidine derivatives as antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-11 | — | — | US | disclosed |
| EP-2024355-A2 | ALKENE PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS | Bristol-Myers Squibb Company (US) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007146550-A2 | ALKENE PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007146550-A2 | ALKENE PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-21 | — | — | WO | disclosed |
| US-20070287730-A1 | Alkene Piperidine Derivatives as Antiviral Agents | BRISTOL-MYERS SQUIBB COMPANY | 2007-12-13 | — | — | US | disclosed |
| US-20070287730-A1 | Alkene Piperidine Derivatives as Antiviral Agents | BRISTOL-MYERS SQUIBB COMPANY | 2007-12-13 | — | — | US | disclosed |
| US-20070287730-A1 | Alkene Piperidine Derivatives as Antiviral Agents | BRISTOL-MYERS SQUIBB COMPANY | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253741-A1 | ALKENE PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS | EIF2AK2, ITPA, MAVS | KMT2A 3595/4885FABP5 1908/4885MEN1 4847/4885 |
| US-20070287730-A1 | Alkene Piperidine Derivatives as Antiviral Agents | EIF2AK2, ITPA, MAVS | KMT2A 3595/4885FABP5 1908/4885MEN1 4847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.